Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have been given an average rating of “Hold” by the six ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.43.
PRTO has been the subject of several research reports. Robert W. Baird reissued a “hold” rating and issued a $2.00 price objective on shares of Proteon Therapeutics in a research report on Friday, November 10th. HC Wainwright reissued a “hold” rating and issued a $2.30 price objective on shares of Proteon Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th.
Proteon Therapeutics (NASDAQ:PRTO) traded down $0.05 on Thursday, hitting $1.85. The stock had a trading volume of 30,787 shares, compared to its average volume of 106,395. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $2.75.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC acquired a new stake in Proteon Therapeutics Inc (NASDAQ:PRTO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics accounts for 0.2% of RA Capital Management LLC’s portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned 7.59% of Proteon Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 50.05% of the company’s stock.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.